Passage BIO, Inc. financial data

Symbol
PASG on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Commerce Square, 2005 Market Street, 39 Th Floor, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 745 % -22.9%
Debt-to-equity 35.3 % +51.3%
Return On Equity -70.7 % -17.9%
Return On Assets -52.3 % -7.48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.8M shares +12.7%
Common Stock, Shares, Outstanding 61.8M shares +12.8%
Entity Public Float 46.8M USD -53.5%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 61.7M shares +12.8%
Weighted Average Number of Shares Outstanding, Diluted 61.7M shares +12.8%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 27.5M USD -43.2%
Operating Income (Loss) -82.5M USD +29.5%
Net Income (Loss) Attributable to Parent -76.6M USD +31.6%
Earnings Per Share, Basic -1.35 USD/shares +34.1%
Earnings Per Share, Diluted -1.35 USD/shares +34.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.8M USD -18.2%
Assets, Current 95M USD -38.2%
Property, Plant and Equipment, Net 13.1M USD -35.5%
Operating Lease, Right-of-Use Asset 16.8M USD -13.3%
Other Assets, Noncurrent 516K USD +19.2%
Assets 125M USD -35.3%
Accounts Payable, Current 621K USD -81.6%
Employee-related Liabilities, Current 3.61M USD -37.6%
Liabilities, Current 12.4M USD -37.7%
Deferred Income Tax Liabilities, Net 5.83M USD -30.8%
Operating Lease, Liability, Noncurrent 22.5M USD -4.11%
Other Liabilities, Noncurrent 2M USD
Liabilities 34.8M USD -19.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -67K USD +80.3%
Retained Earnings (Accumulated Deficit) -627M USD -13.9%
Stockholders' Equity Attributable to Parent 90.6M USD -39.8%
Liabilities and Equity 125M USD -35.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.9M USD +15.7%
Net Cash Provided by (Used in) Financing Activities 8.74M USD
Net Cash Provided by (Used in) Investing Activities 25.3M USD +19%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 61.8M shares +12.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.8M USD -18.2%
Deferred Tax Assets, Valuation Allowance 201M USD +11.6%
Deferred Tax Assets, Gross 207M USD +9.74%
Operating Lease, Liability 26.2M USD -2.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -76.3M USD +31.1%
Lessee, Operating Lease, Liability, to be Paid 43.1M USD -6.75%
Property, Plant and Equipment, Gross 21.9M USD -19.5%
Operating Lease, Liability, Current 3.7M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.76M USD +2.82%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.88M USD +9.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17M USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.86M USD +2.82%
Deferred Tax Assets, Operating Loss Carryforwards 76.4M USD +18.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.97M USD +2.85%
Additional Paid in Capital 718M USD +2.34%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.35M USD -13.6%
Deferred Tax Assets, Net of Valuation Allowance 5.83M USD -30.8%
Share-based Payment Arrangement, Expense 7.57M USD -41.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares